Literature DB >> 12504547

Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.

Young B Kim1, Dong P Han, Carlos Cao, Michael W Cho.   

Abstract

It has been extremely difficult to elicit broadly cross-reactive neutralizing antibodies (Nabs) against human immunodeficiency virus type 1 (HIV-1). In this study, we compared the immunogenic properties of the wild-type and variable loop-deleted HIV-1 envelope glycoproteins. Mice were immunized with recombinant vaccinia viruses expressing either the wild-type or the variable loop-deleted (V1-2, V3, V4, and V1-3) HIV-1(DH12) gp160s. The animals were subsequently boosted with respective recombinant gp120s. All envelope constructs elicited similar levels of gp120-binding antibodies when analyzed by enzyme-linked immunosorbent assay (ELISA). However, the highest neutralizing activity was observed in sera from animals immunized with the wild-type envelope protein, followed by those immunized with DeltaV4 and DeltaV1-2. No neutralizing activity was detected in sera from animals immunized with DeltaV3 or DeltaV1-3. To identify immunogenic epitopes, ELISA was performed with overlapping 15-mer peptides that cover the entire length of gp120. For the wild-type gp120, the immunogenic epitopes mapped primarily to the variable loops V1-2 and to the conserved regions C1 and C5. When they were plotted onto known coordinates of gp120 core crystal structure, the epitopes in the conserved regions mapped predominantly to the inner domain of the protein. By immunizing with variable loop-deleted envelopes, the immune responses could be redirected to other regions of the protein. However, the newly targeted epitopes were neither on the exposed surface of the protein nor on the receptor binding regions. Interestingly, the removal of the V3 loop resulted in loss of immunoreactivity for both V3 and V1/V2 loops, suggesting structural interaction between the two regions. Our results suggest that obtaining broadly reactive Nabs may not be achieved simply by deleting the variable loops of gp120. However, the observation that the immune responses could be redirected by altering the protein composition might allow us to explore alternative strategies for modifying the antigenic properties of HIV-1 envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504547     DOI: 10.1006/viro.2002.1727

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 2.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

3.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

Review 4.  Current advances and challenges in HIV-1 vaccines.

Authors:  Isaac R Rodriguez-Chavez; Mary Allen; Edgar L Hill; Rebecca L Sheets; Michael Pensiero; James A Bradac; M Patricia D'Souza
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

Review 5.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

6.  Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.

Authors:  Y Li; K Svehla; N L Mathy; G Voss; J R Mascola; R Wyatt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

8.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

9.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 10.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.